Jun 25, 2025, 08:45
Women Leaders in Oncology: Tara Frenkl on Hope, Elinzanetant, and HER2+ Lung Cancer Advances
In this inspiring episode of Women Leaders in Oncology, filmed at ASCO 2025, Tara Frenkl, Head of Global Medical & Evidence at Bayer Pharmaceuticals, shares her journey from academic surgeon to pharma leader — and her mission to bring hope to patients and their families through innovative cancer treatments.
Tara reflects on how her clinical background, leadership philosophy, and personal experiences shape her work at Bayer. She speaks openly about balancing leadership with family life, staying true to herself as a woman leader, and fostering empathy and courage in the workplace.
She also highlights key innovations Bayer is presenting at ASCO 2025 — including:
- Elinzanetant (dual NK1/NK3 inhibitor) for managing hot flashes in women on hormone therapy for breast cancer — helping patients stay on treatment and prevent progression.
- SOHO-1 trial findings on a novel TKI for HER2 mutant non-small cell lung cancer — bringing new options to an underserved patient population.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 25, 2025, 08:44
Jun 25, 2025, 08:43
Jun 25, 2025, 08:37